The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach
Open accessAbstract
INTRODUCTION Molecular and immunologic breakthroughs are transforming the management of thoracic cancer, although advances have not been as marked for malignant pleural mesothelioma (MPM) where pathologic diagnosis has been essentially limited to three histologic subtypes. METHODS A multidisciplinary group (pathologists, molecular biologists, surgeons, radiologists and oncologists), sponsored by EURACAN/IASLC met in 2018, to critically review the current classification. RESULTS Recommendations include: 1) classification should be updated to include architectural patterns, and stromal and cytologic features that refine prognostication 2) subject to data accrual, malignant mesothelioma in situ could be an additional category, 3) grading of epithelioid MPMs should be routinely undertaken, 4) favorable/unfavorable histologic characteristics should be routinely reported, 5) clinically relevant molecular data (PD-L1, BAP1, CDKN2A) should be incorporated into reports, if undertaken, 6) other molecular data should be accrued as part of future trials 7) resection specimens (i.e. extended pleurectomy/decortication and extrapleural pneumonectomy) should be pathologically staged with smaller specimens being clinically staged, 8) ideally, at least 3 separate areas should be sampled from the pleural cavity, including areas of interest identified on pre-surgical imaging, 9) image-acquisition protocols/imaging terminology should be standardized to aid research/refine clinical staging, 10) multidisciplinary tumor boards should include pathologists to ensure appropriate treatment options are considered, 11) all histologic subtypes should be considered potential candidates for chemotherapy, 12) patients with sarcomatoid or biphasic mesothelioma should not be excluded from first line clinical trials unless there is a compelling reason, 13) tumor subtyping should be further assessed in relation to duration of response to immunotherapy, 14) systematic screening of all patients for germline mutations is not recommended, in the absence of a family history suspicious for BAP1 syndrome. CONCLUSION These multidisciplinary recommendations for pathology classification and application will allow more informative pathologic reporting and potential risk stratification, to support clinical practice, research investigation and clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
Scherpereel, A., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30765-4 · Cited by 454
Self-citationDisselhorst, M. J., Quispel-Janssen, J., Lalezari, F., Monkhorst, K., de Vries, J. F., van der Noort, V., Harms, E., Burgers, S., & Baas, P. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30420-x · Cited by 250
Self-citationGalateau Salle, F., Le Stang, N., Nicholson, A. G., Pissaloux, D., Churg, A., Klebe, S., Roggli, V. L., Tazelaar, H. D., Vignaud, J. M., Attanoos, R., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.023 · Cited by 93 · cited 3×
“One study suggested a less than 80% cutoff for sarcomatoid areas afforded a better prognosis, and another study showed prognostic significance with a cutoff of 50%.(13,24) However, more data are required before changes are made to the WHO criteria.”
BackgroundSelf-citationHida, T., Hamasaki, M., Matsumoto, S., Sato, A., Tsujimura, T., Kawahara, K., Iwasaki, A., Okamoto, T., Oda, Y., Honda, H., et al. (2016) · Pathology International · doi:10.1111/pin.12453 · Cited by 81
Zauderer, M. G., Szlosarek, P., Le Moulec, S., Popat, S., Taylor, P., Planchard, D., Scherpereel, A., Jahan, T., Koczywas, M., Forster, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.8515 · Cited by 54
Self-citation
Cited by
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273
Self-citationBiomarker Discovery and Validation: Statistical Considerations
Ou, F.-S., Michiels, S., Shyr, Y., Adjei, A. A., & Oberg, A. L. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1616 · Cited by 258
Clinical Significance of Histologic Subtyping of Malignant Pleural Mesothelioma
Brcic, L., & Kern, I. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.38 · Cited by 77
Napoli, F., Listì, A., Zambelli, V., Witel, G., Bironzo, P., Papotti, M., Volante, M., Scagliotti, G., & Righi, L. (2021) · Cancers · doi:10.3390/cancers13112564 · Cited by 22
“by spindle cell morphology (~20% of mesotheliomas), and biphasic, which presents both epithelioid and sarcomatoid features (~20% of mesotheliomas) [3].”
Background
Metadata
- Authors
- Nicholson, A. G., Sauter, J. L., Nowak, A. K., Kindler, H. L., Gill, R. R., Remy-Jardin, M., Armato, S. G., Fernandez-Cuesta, L., Bueno, R., Alcala, N., Foll, M., Pass, H., Attanoos, R., Baas, P., Beasley, M. B., Brcic, L., Butnor, K. J., Chirieac, L. R., Churg, A., Courtiol, P., Dacic, S., De Perrot, M., Frauenfelder, T., Gibbs, A., Hirsch, F. R., Hiroshima, K., Husain, A., Klebe, S., Lantuejoul, S., Moreira, A., Opitz, I., Perol, M., Roden, A., Roggli, V., Scherpereel, A., Tirode, F., Tazelaar, H., Travis, W. D., Tsao, M.-S., van Schil, P., Vignaud, J. M., Weynand, B., Lang-Lazdunski, L., Cree, I., Rusch, V. W., Girard, N., & Galateau-Salle, F.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 15
- Issue
- 1
- Pages
- 29-49
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2974545606
- Cited by
- 168
- References
- 7
- FWCI
- 17.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. https://app.cochat.ai/papers/10.1016/j.jtho.2019.08.2506
- The paper
- Nicholson, A. G., Sauter, J. L., Nowak, A. K., Kindler, H. L., Gill, R. R., Remy-Jardin, M., Armato, S. G., Fernandez-Cuesta, L., Bueno, R., Alcala, N., Foll, M., Pass, H., Attanoos, R., Baas, P., Beasley, M. B., Brcic, L., Butnor, K. J., Chirieac, L. R., Churg, A., . . . Galateau-Salle, F. (2020). EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2019.08.2506
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.